Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
 & Lead Plaintiff Deadline - March 27, 2017 - EconoTimes)
NEW YORK, March 24, 2017 -- -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Aetna Inc. (“Aetna” or the “Company”) (NYSE:AET) and certain of its officers, on behalf of shareholders who purchased Aetna securities between August 15, 2016 and January 20, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/aet.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aetna and its senior executives tried to influence Aetna’s participation in the Public Exchanges for positive treatment from regulators regarding the Humana acquisition; (2) Aetna threatened to limit its involvement in public health insurance exchanges if the Department of Justice (“DOJ”) tried to block the merger; (3) Aetna did not withdraw from certain public health insurance exchanges for business reasons as Defendants claimed, but to follow through on its threat of leaving the marketplace once the DOJ filed suit and to improve its litigation position; (4) Aetna withdrew from public health insurance exchanges that were profitable for Aetna; and (5) consequently, Defendants’ statements regarding Aetna’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/aet or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Aetna you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
